MiNK Therapeutics (INKT) Other Accumulated Expenses (2020 - 2026)

MiNK Therapeutics has reported Other Accumulated Expenses for 7 years, with the latest figure at $2.6 million in Q1 2026.

• Quarterly Other Accumulated Expenses rose 8.41% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (up 8.41% YoY) and the FY2025 annual result came in at $2.8 million, up 20.77% from the prior year.
• Other Accumulated Expenses retreated to $2.6 million in Q1 2026 per INKT's latest filing, from $2.8 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $5.4 million in Q1 2022 and troughed at $2000.0 in Q3 2023.
• A 5-year average of $2.3 million and a median of $2.4 million in 2025 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses jumped 130980.55% in 2022, then slumped 99.9% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $2.6 million in 2022, then slumped by 97.1% to $76000.0 in 2023, then jumped by 3002.5% to $2.4 million in 2024, then increased by 20.77% to $2.8 million in 2025, then dropped by 9.76% to $2.6 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $2.6 million, $2.8 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.